Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. J.W.C. (Jan-Willem) Alffenaar

Research interests

During his routine TDM training he developed great interest into infectious diseases in critically ill patients. His research is focussed on the pharmacokinetics and pharmacodynamics of antimicrobial agents, in particular antifungal agents and anti-TB drugs. The aim is to optimize antimicrobial therapy based on PK/PD principles. The overall aim is to find a balance between efficacy and toxicity. Helpful tools are therapeutic drug monitoring, pharmacokinetic modeling, optimal sampling strategies. Also his more analytical oriented reasearch is focused on optimization of treatment by using alternative sampling strategies like dried blood spot sampling and oral fluid as alternative for plasma and serum.


Analysis of Health-Related Quality of Life and Incurred Costs Among Human Immunodeficiency Virus, Tuberculosis, and Tuberculosis/HIV Coinfected Outpatients in Indonesia

Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations

Tuberculosis impacts multiple aspects in quality of life in a Romanian cohort of drug-susceptible and drug resistant patients: A patient-reported outcome measures study

Bedaquiline exposure in people with drug-resistant TB treated for diabetes: analysis of two phase 2 trials

Clinical standards for the management of adverse effects during treatment for TB

Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study

Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

In reply to comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’

Is it time for new fixed-dose combinations and revised weight bands for children with drug-susceptible TB?

Read more